Additional evidence to support the phasing-out of treatment category II regimen for pulmonary tuberculosis in Peru.
Trans R Soc Trop Med Hyg
; 106(8): 508-10, 2012 Aug.
Article
em En
| MEDLINE
| ID: mdl-22742941
ABSTRACT
The effectiveness of the World Health Organization's (WHO) treatment category II regimen for tuberculosis in 124 patients was compared to that of 1147 patients receiving treatment category I in Lima, Peru following WHO's guidelines. Drug susceptibility test was available for 85% of patients. Prevalence of multi drug resistance and streptomycin resistance were 5.1% and 20.7%, respectively. Overall cure rate for regimen II was lower than that of regimen I 67.8% (95% CI 58.9-75.6.) vs 77.8% (95% CI 75.3-80.2), p=0.014. Multi-drug resistance exerted a profound effect on cure rates in both regimens. Our results support the phasing-out of treatment category II regimen in Peru.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Tuberculose Pulmonar
/
Estreptomicina
/
Tuberculose Resistente a Múltiplos Medicamentos
/
Antituberculosos
Tipo de estudo:
Guideline
/
Risk_factors_studies
Limite:
Adult
/
Female
/
Humans
/
Male
País como assunto:
America do sul
/
Peru
Idioma:
En
Ano de publicação:
2012
Tipo de documento:
Article